Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over

Technology appraisal guidance
Reference number: TA1085
Published: 30 July 2025
Last updated: 30 July 2025

NIHRIO BN: 27712-Vanzacaftor-Tezacaftor-Deutivacaftor-for-Cystic-Fibrosis-V1.0-AUG2023-NON-CONF.pdf (nihr.ac.uk)

This page was last updated: 13 October 2023